New Insights in Estrogen Receptor (ER) Biology and Implications for Treatment
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
http://link.springer.com/content/pdf/10.1007/s12609-017-0231-1.pdf
Reference109 articles.
1. Beatson GW. On the treatment of inoperable carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet. 1896;2:104–7.
2. Taylor CW, Green S, Dalton WS, Martino S, Rector D, Ingle JN, et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol. 1998;16(3):994–9.
3. • Francis PA, Regan MM, Fleming GF, Lang I, Ciruelos E, Bellet M, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372(5):436–46. SOFT was a phase III trial that randomized premenopausal women with early stage hormone receptor positive breast cancer to receive either 5 years of tamoxifen, tamoxifen plus ovarian suppression, or exemestane plus ovarian suppression as adjuvant endocrine therapy. This trial, in conjunction with the TEXT trial, established the use of ovarian suppression in combination with tamoxifen or exemestane as an adjuvant hormonal therapy for premenopausal with high risk hormone receptor positive breast cancer.
4. EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.
5. Early Breast Cancer Trialists’ Collaborative G. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341–52.
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Analysis of Chemotherapy Regimens on Survival Rate of Breast Cancer Patients;2024-01-23
2. Targeting Breast Cancer: The Familiar, the Emerging, and the Uncharted Territories;Biomolecules;2023-08-25
3. Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?;Current Oncology Reports;2020-05-16
4. Structural insight into the antagonistic action of diarylheptanoid on human estrogen receptor alpha;Journal of Biomolecular Structure and Dynamics;2018-03-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3